ARIAD reviews $159.

A suggestion by the independent Data Monitoring Committee as part of its second interim evaluation in the SUCCEED trial that the Phase 3 study continue steadily to its final evaluation of progression-free survival, the primary endpoint of the trial. The ultimate evaluation, to be carried out by Merck, is anticipated by approximately year end. Advancement of ARIAD’s investigational anaplastic lymphoma kinase inhibitor, AP26113, in IND-enabling studies. ARIAD expects to file an investigational new drug application because of this highly potent and molecularly targeted small molecule in mid-2011. Upcoming Medical Interacting with ARIAD scientists will show extra pharmacokinetic and pharmacodynamic data from the ongoing Phase 1 clinical trial of AP24534 in sufferers with advanced blood cancers at the European Society of Haematology’s meeting on chronic myeloid leukemia occurring September 24 to 26, 2010 in Washington, D.C.These new findings could hold tremendous significance not merely for the million+ who sustain TBI from falls, motor vehicle mishaps and assaults in this country each year, but also for returning US armed service veterans.. A new research shows unbelted crash occupants represent 68 % of individuals dying in emergency departments In the nation’s initial statewide study of its kind, the Injury Research Center of the Medical College of Wisconsin in Milwaukee has uncovered new data on an old problem – individuals who avoid seatbelts.